The renin-angiotensin-aldosterone system: Approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease

Cardiology

Volumn 112, Issue 4, 2009, Pages 303-312

  Brugts, J J ^a   Den Uil, C A ^a   Danser, A H J ^a   Boersma, E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitors; Coronary artery disease; Pharmacogenetics; Prevention

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LISINOPRIL; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG EFFECT; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT RESPONSE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 52849126785     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159124     Document Type: Review

References (63)

1. Skeggs LT, Dorer RE, Kahn JR, Lentz KE, Levine M: The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 1976;60:737-748.
2. Erdos EG: Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-370.
3. Perazella MA, Setaro JF: Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003;10:184-194.
4. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, Müller DN, Bader M, Nguyen G, Danser AH: Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007;25:2441-2453.
5. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
6. Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998;16:S3-S9.
7. Szpirer C, Riviere M, Szpirer J, Levan G, Guo DF, Iwai N, Inagami T: Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. J Hypertens 1993;11:919-925.
8. Duncan JA, Scholey JW, Miller JA: Angiotensin type 1-receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens 2001;10:111-116.
9. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ: Human type 2 angiotensin II receptor gene: cloned, mapped to the X-chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994;203:1842-1850.
10. Laragh JH, Angers M, Kelly WG, Lieberman S: Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA 1960;174:234-240.
11. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2000;57:S3-S7.
12. Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-1420.
13. Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angiotensin converting enzyme (AC) inhibitors in renal failure. Clin Pharmacokinet 1993;24:230-254.
14. Pellacani A, Brunner HR, Nussberger J: Plasma kinins increase after angiotensin enzyme inhibition in human subjects. Clin Sci (Lond) 1994;87:567-574.
15. Ferrari R: Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:15-29.
16. Cohn JN: Left ventricle and arteries: structure, function, hormones, and disease. Hypertension 2001;37:346-349.
17. Pitt B: Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995;16:49-54.
18. Kober L, Torp-Pedersen C: Do ACE inhibitors improve outcome in patients with stable vascular disease? Nat Clin Pract Cardiovasc Med 2007;4:124-125.
19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
20. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
21. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
22. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588.
23. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
24. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
25. White HD: Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003;362:755-757.
26. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:1454-1470.
27. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363-2372.
28. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, Remme WJ, Fox K, Simoons ML: Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796-801.
29. Asselbergs FW, van Gilst WH: Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Curr Opin Cardiol 2007;22:267-272.
30. Solomon SD, Rice MM, Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E, Prevention of Events with ACE inhibition (PEACE) Investigators: Renal function and effectiveness of angiotensin- converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114:26-31.
31. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML: The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007;50:2148-2155.
32. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC: Renal function and risk of myocardial infarction in an elderly population: the Rotterdam study. Arch Intern Med 2005;165:2659-2665.
33. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC: A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-1491.
34. Cambien F, Alhenc-Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF, Allegrini J, Bloch C: Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy study. Am J Hum Genet 1988;43:774-780.
35. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetière P, et al.: Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-913.
36. Kamitani A, Rakugi H, Higaki J, Ohishi M, Shi SJ, Takami S, Nakata Y, Higashino Y, Fujii K, Mikami H, et al.: Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 1995;25:950-953.
37. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S: Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600-1603.
38. Winkelmann BR, Russ AP, Nauck M, Klein B, Bohm BO, Maier V, Zotz R, Matheis G, Wolf A, Wieland H, Gross W, Galton DJ, März W: Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999;137:698-705.
39. Rodríguez-Pérez JC, Rodríguez-Esparragón F, Hernández-Perera O, Anabitarte A, Losada A, Medina A, Hernández E, Fiuza D, Avalos O, Yunis C, Ferrario CM: Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. J Am Coll Cardiol 2001;37:1536-1542.
40. Jeunemaitre F, Ledru F, Battaglia S, Guillanneuf MT, Courbon D, Dumont C, Darmon O, Guize L, Guermonprez JL, Diebold B, Ducimetière P: Genetic polymorphisms of the renin angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet 1997;99:66-73.
41. Kee F, Morrison C, Poirier O, McCrum E, Mallet C, Nicaud V, McMaster D, Dallongeville J, Fruchart JC, Evans AE: Angiotensin II type-I receptor and ACE polymorphisms and risk of myocardial infarction in men and women. Eur J Clin Invest 2000;30:1076-1082.
42. Renner W, Nauck M, Winkelmann BR, Hoffmann MM, Scharnagl H, Mayer V, Boehm BO, März W: Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. J Mol Med 2005;83:235-239.
43. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A: Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease. Arterioscler Thromb Vasc Biol 2003;23:1269-1275.
44. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism on the angiotensin I converting enzyme gene accouting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
45. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA: Angiotensin converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-1388.
46. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D: Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
47. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, TI, Miyakawa T, Iwasaki R, Hiramori K: Deletion polymorphism of the angiotensin-1 converting enzyme gene is associated with serum ACE concentrations and increased risk for CAD in the Japanese. Circulation 1994;90:2199-2202.
48. Alvarez R, Reguero JR, Batalia A, Iglesias-Cubero G, Cortina A, Alvarez V: Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism: association with early coronary disease. Cardiovasc Res 1998;40:375-379.
49. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, Hamon M, Richard F, Helbecque N, McFadden EP, Amouyel P, Bertrand ME: D allele of the angiotensin I converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997;96:56-60.
50. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Uslenghi E, Piazza A: Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97:147-154.
51. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Goldstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin- converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-711.
52. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjaerg-Hansen A: ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals: a case referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997;95:2358-2367.
53. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL: A meta-analysis of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation 1996;94:708-712.
54. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A: ACE gene polymorphism in cardiovascular disease: meta-analysis of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000;20:484-492.
55. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R: Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5,000 cases and 6,000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000;355:434-442.
56. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment. Circulation 2005;111:3374-3384.
57. Brugts JJ, Den Uil CA: ACE insertion/deletion polymorphism in sepsis and acute respiratory distress syndrome. Intensive Care Med 2008;34:1733.
58. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Letmaitre RN, Lumley T, Rosendaal FR: Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16:1011-1017.
59. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, Colman S, Leguennec S, MacMahon S, Neal B, Ohkubo T, Woodward MPCG: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003;42:297-303.
60. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
61. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, Kingma JH, Witteman JC, Stricker BH: Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2005;15:75-81.
62. Katzov H, Bennet AM, Kehoe P, Wiman B, Gatz M, Blennow K, Lenhard B, Pedersen NL, de Faire U, Prince JA: A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum Mol Genet 2004;13:2647-2657.
63. Marciante KD, Bis JC, Rieder MJ, Reiner AP, Lumley T, Monks SA, Kooperberg C, Carlson C, Heckbert SR, Psaty BM: Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients. Am J Epidemiol 2007;166:19-27.